Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava)

Human Psychopharmacology

Volumn 19, Issue 4, 2004, Pages 243-250

  Thompson, Richard ^a   Ruch, Willibald ^b   Hasenöhrl, Rüdiger U ^a  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Attention; Exhilaration; Kavapyrones; Mood; Phytopharmacology; Short term memory

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE; HERBACEOUS AGENT; KAVA EXTRACT; KAWAIN; PLACEBO;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EMOTION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MOOD; NORMAL HUMAN; PRIORITY JOURNAL; RATING SCALE; SHORT TERM MEMORY; SINGLE DRUG DOSE; VISION;

ADOLESCENT; ADULT; AFFECT; COGNITION; DOUBLE-BLIND METHOD; FEMALE; HAPPINESS; HUMANS; KAVA; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; TASK PERFORMANCE AND ANALYSIS;

EID: 3042728336     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.581     Document Type: Article

References (46)

1. Baum SS, Hill R, Rommelspacher H. 1998. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry 22: 1105-1120.
2. Bilia AR, Gallon S, Vincieri FF. 2002. Kava-kava and anxiety: growing knowledge about the efficacy and safety. Life Sci 70: 2581-2597.
3. Bliss TV, Collingridge GL. 1993. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361: 31-39.
4. Boonen G, Ferger B, Kuschinsky K, Haberlein H. 1998. In vivo effects of the kavapyrones (+)-dihydromethysticin and (±)-kavain on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions. Planta Med 64: 507-510.
5. Buffett-Jerrott SE, Stewart SH. 2002. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 8: 45-58.
6. Buhot MC, Martin S, Segu L. 2000. Role of serotonin in memory impairment. Ann Med 32: 210-221.
7. Cairney S, Maruff P, Clough AR. 2002. The neurobehavioural effects of kava. Aust N Z J Psychiatry 36: 657-662.
8. Cairney S, Maruff P, Clough AR, Collie A, Currie J, Currie BJ. 2003. Saccade and cognitive impairment associated with kava intoxication. Hum Psychopharmacol 18: 525-533.
9. Davies LP, Drew CA, Duffield P, Johnston GA, Jamieson DD. 1992. Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol 71: 120-126.
10. Dharmaratne HR, Nanayakkara NP, Khan IA. 2002. Kavalactones from Piper methysticum, and their 13C NMR spectroscopic analyses. Phytochemistry 59: 429-433.
11. Dinh LD, Simmen U, Bueter KB, Bueter B, Lundstrom K, Schaffner W. 2001. Interaction of various Piper methysticum cultivars with CNS receptors in vitro. Planta Med 67: 306-311.
12. Gegenfurtner KR, Sperling G. 1993. Information transfer in iconic memory experiments. J Exp Psychol Hum Percept Perform 19: 845-866.
13. Grunze H, Langosch J, Schirrmacher K, Bingmann D, Von Wegerer J, Walden J. 2001. Kava pyrones exert effects on neuronal transmission and transmembraneous cation currents similar to established mood stabilizers - a review. Prog Neuropsychopharmacol Biol Psychiatry 25: 1555-1570.
14. Hänsel R, Woelk H. 1994. Kava Kava, Arzneimitteltherapie heute. Phytopharmaka, Vol. 6. Aesopus: Basel.
15. Hasenöhrl RU, Topic B, Frisch C, Häcker R, Mattern CM, Huston JP. 1998. Dissociation between anxiolytic and hypomnestic effects for combined extracts of Zingiber officinale and Ginkgo biloba, as opposed to diazepam. Pharmacol Biochem Behav 59: 527-535.
16. Heinze HJ, Münthe TF, Steitz J, Matzke M. 1994. Pharmacopsychological effects of oxazepam and kava-extract in a visual search paradigm assessed with event-related potentials. Pharmacopsychiatry 27: 224-230.
17. Holm E, Staedt U, Heep J, et al. 1991. The action profile of D,L-kavain: cerebral sites and sleep-wakefulness-rhythm in animals. Arzneimittelforschung 41: 673-683.
18. Houlihan ME, Pritchard WS, Robinson JH. 2001. Effects of smoking/nicotine on performance and event-related potentials during a short-term memory scanning task. Psychopharmacology 156: 388-396.
19. Jussofie A, Schmiz A, Hiemke C. 1994. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology 116: 469-474.
20. Keledjian J, Duffield PH, Jamieson DD, Lidgard RO, Duffield AM. 1988. Uptake into mouse brain of four compounds present in the psychoactive beverage kava. J Pharm Sci 77: 1003-1006.
21. Langosch JM, Normann C, Schirrmacher K, Berger M, Walden J. 1998. The influence of (±)-kavain on population spikes and long-term potentiation in guinea pig hippocampal slices. Comp Biochem Physiol A Mol Integr Physiol 120: 545-549.
22. Malsch U, Kieser M. 2001. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology 157: 277-283.
23. Meneses A. 1999. 5-HT system and cognition. Neurosci Biobehav Rev 23: 1111-1125.
24. McGaugh JL. 1990. Significance and remembrance: the role of neuromodulatory systems. Psychol Sci 1: 1-15.
25. McGaugh JL. 2000. Memory - a century of consolidation. Science 287: 248-251.
26. McIntyre CK, Power AE, Roozendaal B, McGaugh JL. 2003. Role of the basolateral amygdala in memory consolidation. Ann N Y Acad Sci 985: 273-293.
27. Münte TF, Heinze HJ, Matzke M, Steitz J. 1993. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 27: 46-53.
28. Pittler MH, Ernst E. 2000. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 20: 84-89.
29. Prescott J, Jamieson D, Edmur N, Duffield P. 1993. Acute effects of Kava on measures of cognitive performance, physiological function and mood. Drug Alcohol Rev 12: 49-58.
30. Rex A, Morgenstern E, Fink H. 2002. Anxiolytic-like effects of kava-kava in the elevated plus maze test - a comparison with diazepam. Prog Neuropsychopharmacol Biol Psychiatry 26: 855-860.
31. Ruch W. 1993. Exhilaration and humor. In The Handbook of Emotions, Lewis M, Haviland JM (eds). Guilford Publications: New York; 605-616.
32. Ruch W. 1997. State and trait cheerfulness and the induction of exhilaration. Eur Psychologist 2: 328-341.
33. Ruch W, Köhler G. 1998. A temperament approach to humor. In The Sense of Humor: Explorations of a Personality Characteristic (Humor Research Series, Vol. 3), Ruch W (ed.). Mouton de Gruyter: Berlin; 203-230.
34. Ruch W, Köhler G. 1999. The measurement of state and trait cheerfulness. In Personality Psychology in Europe: Theoretical and Empirical Developments (Vol. 7), Mervielde I, Deary I, De Fruyt F, Ostendorf F (eds). University Press: Tilburg; 67-83.
35. Ruch W, Köhler G, van Thriel C. 1996. Assessing the 'humorous temperament': construction of the facet and standard trait forms of the State-Trait-Cheerfulness-Inventory-STCI. Humor 9: 303-339.
36. Ruch W, Köhler G, van Thriel C. 1997. To be in good or bad humor: construction of the state form of the State-Trait-Cheerfulness-Inventory - STCI. Pers Individ Dif 22: 477-491.
37. Russel PN, Bakker D, Singh NN. 1987. The effects of kava on alerting and speed of access of information from long-term memory. Bull Psychonomic Soc 25: 236-237.
38. Singh YN. 1992. Kava: an overview. J Ethnopharmacol 37: 13-45.
39. Singh YN, Singh NN. 2002. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs 16: 731-743.
40. Sperling G. 1960. The information available in brief visual presentations. Psychol Monogr 74: 1-29.
41. Sternberg S. 1966. High-speed scanning in human memory. Science 153: 652-654.
42. Stevinson C, Huntley A, Ernst E. 2002. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Saf 25: 251-261.
43. Taylor SF, Liberzon I, Fig LM, Decker LR, Minoshima S, Koeppe RA. 1998. The effect of emotional content on visual recognition memory: a PET activation study. Neuroimage 8: 188-197.
44. Volz HP, Kieser M. 1997. Kava-kava extract WS 1490 versus placebo in anxiety disorders - a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 30: 1-5.
45. Walden J, von Wegerer J, Winter U, Berger M, Grunze H. 1997. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 21: 697-706.
46. Wheatley D. 2001. Stress-induced insomnia treated with kava and valerian: singly and in combination. Hum Psychopharmacol 16: 353-356.